tbuckley/cabot-search huggingface dataset:
The Role of Early Cytogenetic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib and the Impact of Adherence and Comorbidities
Authors: Laura Fogliatto, Marcelo Capra, Mariza Shaan, Tito Vanelli Costa, Mayde Seadi Torriani, Katia Fassina, Mario Sérgio Fernandes, Denise Almeida, Marco Antônio Schilling, Tânia Hellwig, Virgínia Coser, Dalnei Veiga Pereira, Waldir Veiga Pereira, Sabrina Wisintainer, Tiago Daltoe, Mariangela Moschen, Adriana Zardo, Juliana Kratochvil, Viviane Magagnin Fernandes, Cheila Eickhoff, Saozan Ahmad, Andréia Dias Almeida, Moema Nene, Nathália Guterres Xavier, Dayane Koshiyama, Márcia Leite, Vitor Lenz, Liane Esteves Daudt, Lucia Silla
Journal: Blood (2011)
A Molecular Signature of the Transcription Factor GATA1 in Acute Megakaryoblastic Leukemia of Childhood.
Authors: Jean-Pierre Bourquin, Claudia Langebrake, Aravind Subramanian, Xiaochun Li, Dirk Reinhardt, Olivier Bernard, Christian M. Zwaan, Henrik Hasle, Martin Schrappe, Todd R. Golub, Stuart H. Orkin
Journal: Blood (2004)
Anti-PR1/HLA-A2 Antibody (8F4, A TCR-Mimic) Mediates Specific Lysis of AML Stem Cells but Not Normal Hematopoietic Stem Cells.
Authors: Anna Sergeeva, Gheath Alatrash, Karen Clise-Dwyer, Kathryn E Quintanilla, Sijie Lu, Qing Ma, Dan Li, Yang Wang, M. James You, Jeffrey J. Molldrem
Journal: Blood (2009)
Longitudinal Analysis of Antibody Response to Immunization in Pediatric Survivors After Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Hiroto Inaba, Meredith Posner, Christine Hartford, Jie Yang, Deqing Pei, Randall Hayden, Ashok Srinivasan, Brandon Triplett, Ching-Hon Pui, Wing Leung
Journal: Blood (2009)
A swollen painful foot
Authors: Joseph Dalby Sinnott, David C Howlett
Journal: BMJ (2016)

A 59 year old woman with diabetes mellitus presented to her general practitioner with a swollen, erythematous, and painful left foot. Her symptoms had been worsening over several months. There was no history of a recent trauma. A plain radiograph was obtained (fig 1⇓). What does this show?



Fig 1  Plain x ray of a left foot



Neuropathic osteoarthropathy, sometimes known as a Charcot foot.

### Discussion

The findings on the radiograph are consistent with advanced neuropathic osteoarthropathy, …
Haematopoietic Stem Cell Transplantation: A Single Centre Experience from Army Hospital (Research &amp; Referral), New Delhi, India
Authors: Velu Nair, Ajay Sharma, Satyaranjan Das, Deepak Kumar Mishra, Jyoti Kotwal, Ridhima Dabas, Vivek Nair, Anil Khetarpal, Alok Sen, O P Mathew
Journal: Blood (2008)
Delayed Redistribution of CD27, CD40 and CD80 Positive B Cells and the Impaired In Vitro Immunoglobulin G Production in Patients with Non-Hodgkin Lymphoma Treated with Rituximab.
Authors: Mitsufumi Nishio, Katsuya Fujimoto, Satoshi Yamamoto, Toshiya Sakai, Kohki Kumano, Masato Obara, Kazuki Koizumi, Masaya Mukai, Norihiro Sato, Takao Koike
Journal: Blood (2006)
The Megaloblastic Anemia of Regional Ileitis
Authors: Frederick Steinberg
Journal: New England Journal of Medicine (1961)

MEGALOBLASTIC anemia occurring in association with lesions of the gastrointestinal tract is unusual but has been reported with a variety of conditions.1 2 3 4 5 6 7 8 9 10 11 12 13 Pictures closely resembling pernicious anemia have been reported to occur in intestinal strictures and anastomosis and have been recognized in the so-called blind-loop syndrome. Few cases of megaloblastic anemia associated with regional enteritis have been reported.1 , 11 , 14 , 15 Crohn and Yarnis,16 in their book on regional ileitis, mention this combination once. Cases that have been described include patients who have had previous surgery, with the creation of a blind, stagnant intestinal loop, or those who manifest the malabsorption syndrome or . . .
DRES-13. EXTENDED TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA: AN ANALYSIS OF THE GERMAN GLIOMA NETWORK
Authors: Dorothee Gramatzki, Philipp Kickingereder, Bettina Hentschel, Ulrich Herrlinger, Gabriele Schackert, Joerg-Christian Tonn, Manfred Westphal, Michael Sabel, Uwe Schlegel, Wolfgang Wick, Guido Reifenberger, Markus Löffler, Martin Bendszus, Michael Weller
Journal: Neuro-Oncology (2016)

The impact of modifying the standard of care for newly diagnosed glioblastoma patients of surgery followed by radiotherapy plus concurrent and 6 cycles of maintenance temozolomide chemotherapy (TMZ/RT->TMZ) by extending TMZ beyond 6 cycles is unclear. The German Glioma Network cohort was screened for glioblastoma patients who received RT plus TMZ and completed at least 6 cycles of maintenance chemotherapy (group A 6 cycles versus group B 37 cycles). Associations of clinical patient characteristics, O6-methylguanine DNA methyltransferase (MGMT)promoter methylation status and residual tumor after 6 cycles of TMZ with progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan-Meier method. Multivariate analyses using the Cox proportional hazards model were performed to assess associations of prolonged TMZ use with outcome. 69 of 154 identified patients received at least 7 maintenance TMZ cycles (median 11, range 7-20). Median PFS (group A, 15.6 months, 95% confidence interval (CI) 9.1-22.0, versus group B 20.0 months, 95% CI 17.1-23.0, p=0.087) and OS (group A 33.2 months, 95% CI 25.4-40.9, versus group B 31.0 months, 95% CI 25.5-36.4, p=0.305) did not differ between groups. There was no significant association of prolonged TMZ chemotherapy with PFS (hazard ratio (HR)=0.7, 95% CI 0.3-1.5, p=0.363) or OS (HR=0.8, 95% CI 0.4-1.7, p=0.524) adjusted for age, extent of resection, Karnofsky Performance Score, presence of residual tumor and MGMT promoter methylation status. In multivariate models relevant hazard ratios for residual tumor (PFS: HR=3.8, 95% CI 1.6-8.9, p=0.003; OS: HR=4.1, 95% CI 1.7-9.8, p=0.001) were observed. MGMT promoter methylation status was associated with HR=0.6 (95% CI 0.3-1.3, p=0.197) for PFS and HR=0.6 (95% CI 0.3-1.4, p=0.251) for OS. These data do not support the practice of prolonging maintenance TMZ chemotherapy beyond 6 cycles, irrespective of MGMT promoter methylation status or residual tumor after 6 cycles.
Long-term Prediction of Cardiovascular Outcomes by Circulating CD34+ and CD34+CD133+ Stem Cells in Patients With Type 2 Diabetes
Authors: Gian Paolo Fadini, Mauro Rigato, Roberta Cappellari, Benedetta Maria Bonora, Angelo Avogaro
Journal: Diabetes Care (2016)

OBJECTIVE Cardiovascular risk varies substantially in the population with diabetes, and biomarkers can improve risk stratification. Circulating stem cells predict future cardiovascular events and death, but data for the population with diabetes are scant. In this study we evaluated the ability of circulating stem cell levels to predict future cardiovascular outcomes and improve risk discrimination in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS A cohort of 187 patients with type 2 diabetes was monitored for a median of 6.1 years. The primary outcome was time to a first cardiovascular event, defined as 3-point major adverse cardiovascular event (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) plus hospitalization for cardiovascular causes. At baseline, we measured six stem/progenitor cell phenotypes in peripheral blood based on expression of CD34, CD133, and KDR. RESULTS The primary outcome occurred in 48 patients (4.5/100 patient-years). Patients with incident cardiovascular events had significantly lower CD34+ and CD34+CD133+ cells than those without. Higher rates of cardiovascular events occurred in patients with below median levels of CD34+ and CD34+CD133+. In Cox proportional hazards regression analyses, a reduced CD34+ (hazard ratio 2.21 [95% CI 1.14–4.29]) and CD34+CD133+ (2.98 [1.46–6.08]) cell count independently predicted future events. Addition of the CD34+ cell count to the reference model or the UK Prospective Diabetes Study risk engine improved C statistics, continuous net reclassification improvement, and/or integrated discrimination index. CONCLUSIONS In patients with type 2 diabetes, a reduced baseline level of circulating CD34+ stem cells predicts adverse cardiovascular outcomes up to 6 years later and improves risk stratification.
A randomized open-label phase I study to assess the effect of vandetanib on vascular permeability in patients with advanced colorectal cancer and liver metastases
Authors: K. Mross, A. Frost, R. Benkelmann, J. Kuhlmann, M. Büchert, U. Fasol, T. P. Milenkova, J. Tessier, A. D. Krebs, R. Fischer
Journal: Journal of Clinical Oncology (2008)

4113 Background: Vandetanib is a once-daily oral inhibitor of VEGFR-2, VEGFR-3, EGFR and RET tyrosine kinases. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was used to assess the effects of vandetanib on tumor perfusion and vascular permeability in patients with advanced colorectal cancer (CRC) and liver metastases. Methods: Eligible patients received vandetanib 100 or 300 mg/day. DCE-MRI (iAUC60 and Ktrans) was used to quantify the primary endpoints of tumor perfusion and vascular permeability. An exploratory assessment of tumor oxygenation was performed using MRI/T2*. All MRI parameters were measured at baseline (twice) and on days 2, 8, 29 and 57. Secondary assessments were pharmacokinetics (PK), safety and tolerability, and a preliminary evaluation of efficacy. Results: Twenty-two patients received vandetanib (n=10, 100 mg; n=12, 300 mg). Baseline measurements of iAUC60 and Ktrans were reproducible, with low intrapatient coefficients of variation (11% and 24%, respectively). Changes from baseline in iAUC60 or Ktrans were not significant in either cohort, with no difference between cohorts (Table). There was a significant increase in T2* at 300 mg compared to 100 mg. Changes in iAUC60 and Ktrans did not appear to correlate with any PK parameter. Both doses of vandetanib were generally well tolerated; the most common toxicities were rash, fatigue, diarrhea, dysphonia and hypertension (majority CTC grade 1 or 2). RECIST evaluation showed no objective tumor responses, with stable disease ≥8 weeks in five patients receiving vandetanib 300 mg. Conclusions: In this study of patients with CRC, vandetanib (100 or 300 mg) did not reduce tumor vascular perfusion and permeability as measured by DCE-MRI. The T2* increase at 300 mg is attributed to increased tumor necrosis. Vandetanib continues to be investigated in CRC and a range of other tumor types, including Phase III evaluation in NSCLC and medullary thyroid cancer. Change from baseline in MRI parameters Parameter Mean % change from baseline (95% CI) P-value (300 mg vs 100 mg) Vandetanib 100 mg Vandetanib 300 mg iAUC60 -3.4 (-13.6, 8.1) -4.6 (-13.4, 5.0) 0.429 Ktrans 4.6 (-22.4, 17.4) 2.7 (-18.4, 16.2) 0.558 T2* -2.2 (-7.1, 2.9) 7.3 (3.1, 11.7) 0.006 Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration AstraZeneca Oncology AstraZeneca
Uncommon Presentations of Malignancies
Authors: David Atallah, Georges Chahine, Ioannis A. Voutsadakis
Journal: Journal of Clinical Oncology (2003)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2003.07.105 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12885822 Uncommon Presentations of Malignancies CASE 3. BRAIN METASTASIS FROM OVARIAN CANCER David AtallahxDavid AtallahSearch for articles by this author , Georges ChahinexGeorges ChahineSearch for articles by this author , Ioannis A. VoutsadakisxIoannis A. VoutsadakisSearch for articles by this author Show More Institut Gustave-Roussy, Villejuif, France https://doi.org/10.1200/JCO.2003.07.105 First Page Full Text PDF Figures and Tables © 2003 by American Society of Clinical Oncology
Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review &amp; Meta-Analysis of Observational Studies.
Authors: Lisa K Lütkhoff, Manuela Albisetti, Timothy J. Bernard, Mariana Bonduel, Leonardo R. Brandao, Stephane Chabrier, Anthony Chan, Barbara Fiedler, Heather J. Fullerton, Vijeja Ganesan, Neil A Goldenberg, Meredith Golomb, Eric F. Grabowski, Christine Heller, Susanne Holzhauer, Alfonso Iorio, Janna Journeycake, Gili Kenet, Fenella J Kirkham, Karin Kurnik, John K Lynch, Christoph Male, Marilyn J. Manco-Johnson, Rolf Mesters, Paul Monagle, Heleen C van Ommen, Leslie Raffini, Paolo Simioni, Ronald Straeter, Guy Young, Ulrike Nowak-Gottl
Journal: Blood (2009)
A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma
Authors: Eckard Hamelmann, Jonathan A. Bernstein, Mark Vandewalker, Petra Moroni-Zentgraf, Daniela Verri, Anna Unseld, Michael Engel, Attilio L. Boner
Journal: European Respiratory Journal (2016)

We present results from the first phase III trial of once-daily tiotropium add-on to inhaled corticosteroids (ICS) plus one or more controller therapies in adolescents with severe symptomatic asthma. In this double-blind, parallel-group trial ( NCT01277523 ), 392 patients aged 12–17 years were randomised to receive once-daily tiotropium 5 µg or 2.5 µg, or placebo, as an add-on to ICS plus other controller therapies over 12 weeks. The primary and key secondary end-points were change from baseline (response) in peak forced expiratory volume in 1 s (FEV 1 ) within 3 h post-dosing (FEV 1(0–3h) ) and trough FEV 1 , respectively, after 12 weeks of treatment. Tiotropium 5 µg provided numerical improvements in peak FEV 1(0–3h) response, compared with placebo (90 mL; p=0.104), and significant improvements were observed with tiotropium 2.5 µg (111 mL; p=0.046). Numerical improvements in trough FEV 1 response and asthma control were observed with both tiotropium doses, compared with placebo. The safety and tolerability of tiotropium were comparable with those of placebo. Once-daily tiotropium Respimat add-on to ICS plus one or more controller therapies in adolescents with severe symptomatic asthma was well tolerated. The primary end-point of efficacy was not met, although positive trends for improvements in lung function and asthma control were observed.
First-line docetaxel (Dx) and capecitabine (Cap) in advanced head and neck cancer
Authors: A. Gil-Negrete, J. M. Mañe, A. Ruiz de Lobera, A. Martinez-Bueno, I. Rubio, N. Fuente, G. Lopez-Vivanco, N. Ancizar, R. Fernandez, A. Sancho
Journal: Journal of Clinical Oncology (2007)

16505 Background: Dx and Cap are useful drugs in head and neck cancer. Our purpose was to establish the efficacy and safety of this combination in non selected patients (pts) with advanced or metastatic (M1) head and neck cancer. Methods: : Between Apr 2005 and Nov 2006, 33 pts with squamous cell locally advanced or M1 head and neck cancer received the following chemotherapy (Ct) schedule: Dx 75 mg/m2 day 1 and Cap 950 mg/m2/12h days 2–14, every 3 weeks.30 pts (90.9%) had received previous local radiotherapy, 11 of them with concomitant Ct. Results: Mean age was 60 years old (range 46–75). M/F: 32/1. PS 0/1/2: 1/29/3. Location of disease: only local 49%; local and M1 36%; only M1 15% (Main M1 site: lung 76.5%, nodes 11.8%, bone 5.9%, soft tissue 5.9%). Mean number of Ct cycles: 4 (range 1–7). Worst hematologic toxicities per patient G3/G4 (%): neutropenia 6/39; febrile neutropenia 36/0; anemia 3/0; trombopenia 3/3. Non-hematologic toxicities G2/G3 (%): vomiting 3/3; neuropathy 6/0; asthenia 33/6; diarrhea 21/3; mucositis 33/18; nail changes 12/0; hand foot syndrome 3/12. Other events to remark: 4 pts had neumonia (2 toxic deaths), 1 pts had angor and required a different Ct schedule, 2 pts had massive hemorrage (1 exitus). There were 7 pts not evaluable for response (4 not yet evaluated, 1 early death due to massive hemorrage, 1 toxic death due to neumonia, 1 early disphagia). Among the evaluated pts, responses were: 2 CR (7.7%), 10 PR (38.5%), 9 SD (34.6%) and 5 PD (19.2%). Median TTP was 21 weeks (95%CI 17.5 - 24.2). Median OS was 39.8 weeks (95%CI 32.4 - 47.4) by Kaplan-Meier method. Conclusions: This combination appears to be active in pts with advanced or M1 head and neck cancer. Main toxicities were neutropenia, febrile neutropenia, mucositis and asthenia. Global toxicity was important with two toxic deaths documented No significant financial relationships to disclose.
Donor KIR Tel-B Haplotypes Beneficially Affect Outcome after Allogeneic Stem Cell Transplantation in Patients with Myeloid Malignancies
Authors: Ekaterina G Khamaganova, Elena N. Parovichnikova, Larisa A Kuzmina, Sergey M. Kulikov, Valeri G Savchenko
Journal: Blood (2014)
Effects of Immunosuppressive Drugs on Hematopoietic Engraftment after Simultaneous Infusion of Apoptotic Cells and Bone Marrow Cells.
Authors: Emeline Masson, François Kleinclauss, Sylvain Perruche, Amandine Radlovic, Hugues Bittard, Eric Deconinck, Pierre Tiberghien, Philippe Saas
Journal: Blood (2005)
Korea Brain Initiative: Integration and Control of Brain Functions
Authors: Sung-Jin Jeong, Haejin Lee, Eun-Mi Hur, Youngshik Choe, Ja Wook Koo, Jong-Cheol Rah, Kea Joo Lee, Hyun-Ho Lim, Woong Sun, Cheil Moon, Kyungjin Kim
Journal: Neuron (2016)
Imatinib in Very Elderly (&gt; 75 years) CML Patients: Are Low-Doses (&lt;400 mg daily) Enough?
Authors: Roberto Latagliata, Massimo Breccia, Dario Ferrero, Francesco Cavazzini, Malgorzata Monika Trawinska, Fausto Castagnetti, Mario Annunziata, Fabio Stagno, Mario Tiribelli, Silvia Imbergamo, Carmen Fava, Elena Crisà, Giuseppe Pietrantuono, Antonella Gozzini, Franca Falzetti, Enrico Montefusco, Alessandra Iurlo, Caterina Musolino, Michele Cedrone, Antonella Russo Rossi, Patrizia Pregno, Giuseppe Visani, Isabella Capodanno, Mauro Endri, Antonio Spadea, Gianfranco Giglio, Francesca Celesti, Simona Sica, Sergio Storti, Ada M D'Addosio, Giovanna Rege Cambrin, Luigiana Luciano, Elisabetta Abruzzese, Gianantonio Rosti, Giuliana Alimena
Journal: Blood (2011)
Allo-HSCT From Unrelated Donors Improves The Outcome Of Elderly AML Patients In CR1
Authors: Yosuke Nagahata, Yuichiro Ono, Yotaro Ochi, Yusuke Koba, Yasuhiro Kazuma, June Takeda, Yuki Funayama, Nobuhiko Yamauchi, Nobuhiro Hiramoto, Sumie Tabata, Noboru Yonetani, Akiko Matsushita, Hisako Hashimoto, Takayuki Ishikawa
Journal: Blood (2013)
Social, not individual, identification is the key to understanding group phenomena
Authors: Rupert Brown
Journal: Behavioral and Brain Sciences (2016)

Abstract Baumeister and colleagues argue for the indispensability of groups in human life. Yet, in positing individual differentiation as the key to effective group functioning, they adopt a Western-centric view of the relationship of the individual to the group and overlook an alternative social identity account in which depersonalisation, not individuation, is central to understanding many group phenomena.
R-CHOP Therapy Cannot Overcome CD5 Positive Non-GCB Subtype of DLBCL
Authors: Yuko Mishima, Masahiro Yokoyama, Noriko Nishimura, Kyoko Ueda, Tadahiro Gunji, Hideaki Nitta, Yoshiharu Kusano, Norihito Inoue, Anna Takahashi, Naoko Tsuyama, Kengo Takeuchi, Yasuhito Terui, Kiyohiko Hatake
Journal: Blood (2015)
18F-FDG PET/CT Metabolic Tumor Volume and Intratumoral Heterogeneity in Pancreatic Adenocarcinomas
Authors: Esther Mena, Sara Sheikhbahaei, Mehdi Taghipour, Abhinav K. Jha, Esther Vicente, Jennifer Xiao, Rathan M. Subramaniam
Journal: Clinical Nuclear Medicine (2016)

We aimed to determine the consistency of quantitative PET measurements of metabolic tumor volume (MTV) and intratumoral heterogeneity index for primary untreated pancreatic adenocarcinomas, when using dual-time point F-FDG PET/CT imaging.This is an institutional review board-approved, retrospective study including 71 patients with pancreatic adenocarcinoma, who underwent dual-time point F-FDG PET/CT imaging, at approximately 1 hour (early) and 2 hours (delayed), after injection. Automated gradient-based and 50% SUVmax-threshold segmentation methods were used to assess the primary tumor MTV and metabolic intratumoral heterogeneity index, calculated as the area under cumulative SUV-volume histograms (AUC-CSH), with lower AUC-CHS indexes corresponding to higher degrees of tumor heterogeneity. We defined that more than a ±10% change in MTV or AUC-CSH, compared with baseline, as clinically significant.Seventy-one FDG-avid pancreatic tumors were identified, with an average tumor diameter of 3.4 ± 0.9 cm (range, 1.5-6.4 cm). Metabolic tumor volume values remained consistent between early and delayed imaging when using the gradient PET segmentation method (P = 0.086), whereas statistically significant change was seen when using 50% SUVmax-threshold segmentation (P < 0.001). A decrease in more than 10% change in MTV (% ΔMTV) was observed in 70.4% (50/71) tumors, and 7.0% (5/71) of the tumors showed an increase more than 10 % ΔMTV, when using the 50% SUVmax-threshold segmentation. AUC-CSH indexes showed statistically significant differences between early and delayed time points (P < 0.001), when using the gradient segmentation. AUC-CSH index decreased by 10% or greater in 40.8% (29/71) of the tumors. AUC-CSH index remained stable between early and delayed when using the 50% SUVmax-threshold segmentation (P = 0.148) with percentage of change of less than 10% for all tumors.Metabolic tumor volume was relatively stable between early and delayed time points when PET gradient segmentation was used but changed greater than 10% in 77.4% of the tumors at delayed time point when threshold segmentation was used. The tumor heterogeneity index (AUC-CSH) changed greater than 10% in 40.8% of tumors at delayed imaging, when gradient segmentation was used but remained stable when threshold segmentation was used. It is important to standardize uptake time and segmentation methods to use FDG PET MTV and heterogeneity index as imaging biomarkers.
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT
Authors: Christine E. Ryan, Bita Sahaf, Aaron C. Logan, Susan O’Brien, John C. Byrd, Peter Hillmen, Jennifer R. Brown, Martin J. S. Dyer, Anthony R. Mato, Michael J. Keating, Samantha Jaglowski, Fong Clow, Andrew R. Rezvani, Lori Styles, Steven E. Coutre, David B. Miklos
Journal: Blood (2016)
Phase II Study of GM-CSF, IL-2 and Rituximab Immunomodulation Following Autologous Stem Cell Transplantation in Patients with Relapsed or Refractory Lymphomas
Authors: Xavi er Poiré, Justin Kline, Kathy Conner, Todd M. Zimmerman, Koen van Besien, Sonali Smith
Journal: Blood (2008)
Challenges in Oncology
Authors: B. Jay Brooks, J. Cary Bani, Christopher D.M. Fletcher, George D. Demetri
Journal: Journal of Clinical Oncology (2002)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.3.870 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11821475 Challenges in Oncology Case 4. Response of Metastatic Gastrointestinal Stromal Tumor Including CNS Involvement to Imatinib Mesylate (STI-571) B. Jay BrooksxB. Jay BrooksSearch for articles by this author , J. Cary BanixJ. Cary BaniSearch for articles by this author , Christopher D.M. FletcherxChristopher D.M. FletcherSearch for articles by this author , George D. DemetrixGeorge D. DemetriSearch for articles by this author Show More Ochsner Clinic Foundation, Baton Rouge, LA; and Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA https://doi.org/10.1200/JCO.2002.20.3.870 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology